Effect of GLP-1 on Lipid Metabolism in Human Adipocytes
The DOI matches its Crossref record.
Abstract
We have studied the effect of several doses of GLP-1, compared to that of insulin and glucagons, on lipogenesis, lipolysis and cAMP cellular content, in human adipocytes isolated from normal subjects. In human adipocytes, GLP-1 exerts a dual action, depending upon the dose, on lipid metabolism, being lipogenic at low concentrations of the peptide (ED50, 10(-12) M), and lipolytic only at doses 10-100 times higher (ED50, 10(-10) M); both effects are time- and GLP-1 concentration-dependent. The GLP-1 lipogenic effect is equal in magnitude to that of equimolar amounts of insulin; both hormones apparently act synergically, and their respective action is abolished by glucagon. The lipolytic effect of GLP-1 is comparable to that of glucagon, apparently additive to it, and the stimulated value induced by either one is neutralized by the presence of insulin. In the absence of IBMX, GLP-1, at 10(-13) and 10(-12) M, only lipogenic doses, does not modify the cellular content of cAMP, while from 10(-11) M to 10(-9) M, also lipolytic concentrations, it has an increasing effect; in the presence of IBMX, GLP-1 at already 10(-12) M increased the cellular cAMP content. In human adipocytes, GLP-1 shows glucagon- and also insulin-like effects on lipid metabolism, suggesting the possibility of GLP-1 activating two distinct receptors, one of them similar or equal to the pancreatic one, accounting cAMP as a second messenger only for the lipolytic action of the peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to experimental research, GLP-1 can certainly cause both lipogenic and lipolytic effects in a dose-dependent manner, with lipogenic action predominating at picomolar concentrations and lipolytic action at nanomolar doses [59,60,61,62,63].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [61]
Citations
Cites
Still being checked.
Cited by
Items 101–113 of 113
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
Incretins, Incretinmimetics, Inhibitors (2 nd part)
Bayón, C., Araceli, B. M., & de León, L. F.-D. (2010)
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
Stinkens (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20171005rs
Developmental Origins and Roles of Intestinal Enteroendocrine Hormones
Jonnakuti, V. S., Stanescu, D. E., & León, D. D. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00035-0
Modulation of fat oxidation: nutritional and pharmacological approach
van Can, J. G. P. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121031jc
Metabolic and Digestive Functions of Glucagon-Like Peptide-1 in Pigs
Čulka, Ľ., Krepelková, Z., Bárdová, K., & Novotny, J. F. (2026) · Folia veterinaria · doi:10.2478/fv-2026-0018
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Metadata
- Authors
- Villanueva-Peñacarrillo, M. L., Márquez, L., González, N., Díaz-Miguel*, M., & Valverde, I.
- ORCID
- González, N.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 33
- Issue
- 2
- Pages
- 73-77
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2029102093
- Cited by
- 113
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 6
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- glucagon-like peptide-1, human adipocytes, lipid metabolism, lipogenesis, lipolysis, insulin, glucagon, cyclic AMP, dose-dependent effects, hormone synergy, 3-isobutyl-1-methylxanthine, second messengers
- MeSH terms
- Cyclic AMP, Dose-Response Relationship, Drug, Female, Glucagon, Humans, Lipids, Lipolysis, Male, Middle Aged, Peptide Fragments, Protein Precursors, 1-Methyl-3-isobutylxanthine, Adipocytes, Lipid Metabolism, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.